The photoelectron momentum distributions with respect to the molecular axis shown in Fig. 2 were generated in the following way. Initially, the ions were assigned to the one of the two breakup channels, direct and indirect, by requiring the magnitude of the ion momentum to be within 3.5–17 a.u. and 37–46 a.u., respectively. This gating ensure that the ion comes from the breakup of the dimer along II(1/2)g state (Fig. 1a ). The ionization of atomic neon as well as dissociation over the other potential curves43 (link) would result in the ion momentum smaller than 3 a.u. Subsequently, only ionization events have been considered, where ion and electron momentum vectors lie within slices along the polarization plane, defined by the conditions |px| < 0.55 a.u. for electrons as well as |px| < 3.5 a.u. and |px| < 12.0 a.u. for ions from the direct and indirect dissociation channels, respectively (the x-direction is the light propagation direction). These conditions ensure that the angle between a momentum vector and the polarization plane does not exceed 45° in the worst case. For the majority of events this angle is, however, smaller than 30°. Both, electron and ion momentum vectors were projected onto the polarization plane. The projection of the ion momentum defines the k|| direction, whereas the two components, k|| and k⊥, of the electron projection are plotted in Fig. 2 . This type of molecular frame transformation avoids nodes along the dimer axis. It does not conserve the product k·R , but the loss of contrast in the interference patterns is negligible. Another type of transformation, a natural one, where the ion momentum vector, not its projection, defines the k|| direction is presented in the Supplementary Note 3 and Supplementary Fig. 4 .
>
Chemicals & Drugs
>
Amino Acid
>
Product R
Product R
Product R: An innovative AI-powered research platform that streamlines the discovery and comparison of scientific protocols.
Leveraging extensive data from literature, preprints, and patents, PubCompare.ai empowers researchers to identify the most relevant and effective protocols for their needs.
With intuitive tools for protocol alignment and optimization, the platform helps users optimize their research workflow and stay ahead of the curve.
Experience the future of research today with PubCompare.ai's cutting-edge technology and seamless user experince.
Leveraging extensive data from literature, preprints, and patents, PubCompare.ai empowers researchers to identify the most relevant and effective protocols for their needs.
With intuitive tools for protocol alignment and optimization, the platform helps users optimize their research workflow and stay ahead of the curve.
Experience the future of research today with PubCompare.ai's cutting-edge technology and seamless user experince.
Most cited protocols related to «Product R»
Cloning Vectors
Electrons
Epistropheus
Light
Neon
Product R
Reading Frames
Adiposity
Human Body
Product R
In contrast to previous methods, CIBERSORT produces an empirical P value for the deconvolution using Monte Carlo sampling. This approach allows CIBERSORT to test the null hypothesis that no cell types in the signature matrix (e.g., LM22) are present in a given GEP mixture, m. For this purpose, we use the Pearson product-moment correlation R calculated between m and f x B as the test statistic, though other distance metrics could be used. In order to derive an empirical P value, CIBERSORT must first derive a null distribution R*. Because the signature matrix B will contain only a small subset of genes g compared to the whole transcriptome, g expression values are randomly drawn from the parent GEP of m to create a random mixture m *i, such that |m | = |m *i|. CIBERSORT is then run on m *i to produce a vector of estimated cellular fractions, f *i. CIBERSORT determines the correlation coefficient R*i between the random mixture m *i and the reconstituted mixture, f *i x B . This process is repeated for I iterations (=500 in this work) to produce R*.
Cells
Cloning Vectors
Genes, vif
Parent
Product R
Transcriptome
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Confined Spaces
Disease Outbreaks
Epidemics
Exhaling
Filtration
Infection
Maritally Unattached
Pathogenicity
Product R
Reproduction
Respiratory Rate
Transmission, Communicable Disease
Virion
Virus
Virus Inactivation
Alleles
Allogeneic Cells
Animals
antibiotic G 418
Chimera
Clone Cells
Cloning Vectors
Embryo
Embryonic Stem Cells
Genes
Genome
Genotype
Institutional Animal Care and Use Committees
Internal Ribosome Entry Sites
KB 11
Malignant Neoplasms
Mus
Neomycin
Oligonucleotide Primers
Polyadenylation
Product R
Recombinant DNA
Simian virus 40
SOX9 protein, human
Specific Pathogen Free
Untranslated Regions
Most recents protocols related to «Product R»
The data was analyzed using RStudio Version 2022.12.0 + 35352 . The analysis is split into two parts. In the first part we tested for differences between the means of the considered variables across the dosage levels. Model assumptions were checked using the Shapiro–Wilk test of normality and the Brown-Forsythe test of variance equality via the R functions shapiro.test and bf.test. If there was no evidence of non-normality and no evidence of variance inequality, the data were analyzed using a one-way analysis of variance (ANOVA, R function: aov). If there was no evidence of non-normality, but there was evidence of variance inequality, the data were analyzed using Welch’s ANOVA (R function: oneway.test). If there was evidence of non-normality, the data were analyzed with the Kruskal–Wallis test (R function kruskal.test). Post-hoc analyses were performed using either Dunnett’s test, the Games-Howell post hoc test, or Dunn’s test using the R functions dunnettTest, games_howell_test, or dunnTest, respectively. In the second part we studied the relationships between the variables of interest. The goals were to determine whether significant correlations exist and if one, or a combination, of these variables can be considered indicative of anxiety. To study the relationships between the variables we used Pearson’s product moment correlation coefficient via the R function cor.test53 and a principal component analysis (PCA) via the R function prcomp52 . Following the PCA, we submitted the observations values on the principal components to a permutation testing scheme54 (link). The purpose of this permutation testing scheme was to test for statistical differences between each dosage level. We used the R functions aovp55 and perm.test56 to run these permutation tests. These functions implement modified versions of the standard one-way ANOVA and multiple comparison procedures used in part one of our analysis. For all permutation tests, we used a seed with value 2022. The 5% significance level was used for assessing statistical significance in all tests. Summary statistics are presented as represented as mean ± S.E.M.
Anxiety
neuro-oncological ventral antigen 2, human
Product R
Progressive Encephalomyelitis with Rigidity
Calves were randomly assigned to receive either RSB or a sham injection by means of a random number generator (www.randomizer.org ). Calves in the RSB group received a rectus sheath injection with 0.3 ml/kg 0.25% bupivacaine HCl (Bupivacaina Recordati; Recordati S.p.A., Italy) containing dexmedetomidine HCl (1 μg/ml; Dexdomitor 0.5 mg/ml; Zoetis Inc., United States) as an adjuvant to prolong the effect of the local anesthetic, as previously described (28 (link), 29 (link)). Calves in the control group received a rectus sheath injection with an equivalent volume of sterile saline (0.9% NaCl). All injections were administered by the same operator (FM).
A 14-gauge catheter (Introcan Safety; BBraun Milano S.p.A., Italy) was aseptically placed in one of the jugular veins. Calves were allowed to rest in a quiet room for 120 min prior to induction of anesthesia. All procedures were performed in a dedicated clean area outside the barn. The area was protected from direct sun and well-ventilated. After premedication with an intravenous (IV) injection of 0.02–0.05 mg/kg xylazine (Nerfasin 100 mg/ml; Ati S.r.l., Italy) and 0.02 mg/kg butorphanol (Alvegesic 10 mg/ml; Dechra Veterinary Products S.r.l., Italy), anesthesia was induced with 2.5 mg/kg IV ketamine (Lobotor 100 mg/ml; ACME S.r.l., Italy). All calves were positioned in dorsal recumbency, raised from the ground, and laterally content by straw bales, with legs secured far from the surgical field and with the head elevated and the tip of the nose down to avoid aspiration. Intraoperative monitoring included heart rate (HR) determined by auscultation with a stethoscope, respiratory rate (fR) calculated by direct observation of the thoracic excursions, arterial hemoglobin saturation of oxygen (SpO2) measured with a portable pulse oximeter (CMS-50D1 Fingertip Pulse Oximeter; AccuMed, TX, United States), and rectal temperature. Data were continuously monitored and recorded every 5 min throughout the procedure. At baseline, skin incision, and at the end of surgery, a venous blood sample was collected in a heparinized syringe and analyzed immediately using an automated bench-top blood-gas analyzer (iSTAT 1 Analyser; VetScan, United States) for monitoring ventilation and electrolyte status.
If the calf responded to surgical stimulation with gross movement, spontaneous blinking, nystagmus, or increased jaw tone, additional boluses of IV ketamine (0.5 mg/kg) and/or xylazine (0.01 mg/kg) were administered. At the end of the surgical procedure, 1.1 mg/kg of flunixin meglumine (Alivios; Fatro S.p.A., Italy) was administered IV, and calves were positioned in sternal recumbency, with the neck extended forward for recovery. The time elapsed between the end of the surgery and the animal being able to hold sternal position without support (time-to-sternal) and the time from sternal recumbency to stand (time-to-stand) were recorded.
A 14-gauge catheter (Introcan Safety; BBraun Milano S.p.A., Italy) was aseptically placed in one of the jugular veins. Calves were allowed to rest in a quiet room for 120 min prior to induction of anesthesia. All procedures were performed in a dedicated clean area outside the barn. The area was protected from direct sun and well-ventilated. After premedication with an intravenous (IV) injection of 0.02–0.05 mg/kg xylazine (Nerfasin 100 mg/ml; Ati S.r.l., Italy) and 0.02 mg/kg butorphanol (Alvegesic 10 mg/ml; Dechra Veterinary Products S.r.l., Italy), anesthesia was induced with 2.5 mg/kg IV ketamine (Lobotor 100 mg/ml; ACME S.r.l., Italy). All calves were positioned in dorsal recumbency, raised from the ground, and laterally content by straw bales, with legs secured far from the surgical field and with the head elevated and the tip of the nose down to avoid aspiration. Intraoperative monitoring included heart rate (HR) determined by auscultation with a stethoscope, respiratory rate (fR) calculated by direct observation of the thoracic excursions, arterial hemoglobin saturation of oxygen (SpO2) measured with a portable pulse oximeter (CMS-50D1 Fingertip Pulse Oximeter; AccuMed, TX, United States), and rectal temperature. Data were continuously monitored and recorded every 5 min throughout the procedure. At baseline, skin incision, and at the end of surgery, a venous blood sample was collected in a heparinized syringe and analyzed immediately using an automated bench-top blood-gas analyzer (iSTAT 1 Analyser; VetScan, United States) for monitoring ventilation and electrolyte status.
If the calf responded to surgical stimulation with gross movement, spontaneous blinking, nystagmus, or increased jaw tone, additional boluses of IV ketamine (0.5 mg/kg) and/or xylazine (0.01 mg/kg) were administered. At the end of the surgical procedure, 1.1 mg/kg of flunixin meglumine (Alivios; Fatro S.p.A., Italy) was administered IV, and calves were positioned in sternal recumbency, with the neck extended forward for recovery. The time elapsed between the end of the surgery and the animal being able to hold sternal position without support (time-to-sternal) and the time from sternal recumbency to stand (time-to-stand) were recorded.
Anesthesia
Anesthetic Effect
Animals
Arteries
Auscultation
BLOOD
Bupivacaine
Bupivacaine Hydrochloride
Butorphanol
Catheters
Electrolytes
flunixin meglumine
Head
Hemoglobin
Hydrochloride, Dexmedetomidine
Jugular Vein
Ketamine
Leg
Movement
Neck
Normal Saline
Nose
Operative Surgical Procedures
Oximetry
Oxygen
Oxygen Saturation
Pathologic Nystagmus
Pharmaceutical Adjuvants
Premedication
Product R
Pulse Rate
Rate, Heart
Rectum
Respiratory Rate
Safety
Saline Solution
Saturation of Peripheral Oxygen
Scheuermann's Disease
Skin
Sterility, Reproductive
Sternum
Stethoscopes
Syringes
Veins
Xylazine
The statistical analyses were performed using SPSS (IBM Corp. Released 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp). For the non-parametric variables (RPE, RPD, sPDF and EES) the Friedman test was used to detect differences between the sessions. If differences were detected, the Wilcoxon signed rank test was used to identify where the differences lay. These results are presented as median ± interquartile range. For the parametric variables (Training volume, StO2 and lactate) normality was checked and confirmed by visual inspection. Differences between the sessions were assessed with one-way repeated measures ANOVAs with Bonferroni post hoc tests. These results are presented as mean ± standard deviation (SD). Effect size for the parametric variables is presented as Cohen`s d effect size (d) and was calculated using the following equation: mean session 1–mean session 2 divided by the standard deviations of the difference. An effect size of 0.2–0.5 was considered small, 0.5–0.8 medium and > 0.8 large43 . For the non-parametric variables effect size was calculated as product-movement r (r) using the following equation: r = z/√n, with z being the z-value of the Wilcoxon signed ranked test and n being the number of participants. A product-movement r of 0.1–0.29 was considered small, 0.3–0.49 medium and ≥ 0.5 large43 . Statistical difference was accepted at p < 0.05.
Lactate
Movement
neuro-oncological ventral antigen 2, human
Product R
A total number of 60 adults (~4 months of age), both sexes (male:female 50:50 ratio), of wild-type, short-fin strain of zebrafish (Danio rerio) were purchased from an authorized commercial supplier (Pet Product S.R.L, Bucharest, Romania). The animals were housed in pairs of 10 in tanks filled with 30 L of dechlorinated water with well-established parameters: 27 ± 1 °C temperature, 7–7.2 pH, 7.2 mg O2/L, 1500–1600 µS/cm conductivity. The fish were fed twice daily with Norwin Norvital flake (Norwin, Gadstrup, Denmark) and were kept under 12 h light/dark cycle. The water was exchanged once every 3 days. The study was conducted according to the guidelines of the 2010/63/EU Directive of the European Parliament, and it was approved by the Ethics Committee on Animal Research of the Faculty of Biology, Alexandru Ioan Cuza University of Iași, Romania (no. 02/30.06.2020).
The animals were assigned to 6 experimental groups (10 fish/group) as follows: (I) Control; (II) SCOP (fish treated with 100 µM SCOP); (III) SCOP + GAL 1 mg/L (fish treated with 100 µM SCOP and 1 mg/L GAL); (IV) SCOP + IMP 20 mg/L (fish treated with 100 µM SCOP and 20 mg/L IMP); (V) SCOP + GCEO 25 µL/L (fish treated with 100 µM SCOP and 25 µL/L GCEO); (VI) SCOP + GCEO 150 µ/L (fish treated with 100 µM SCOP and 150 µL/L GCEO). Groups I, II, III and IV received 1% Tween 80 as vehicle. GCEO was prepared in 1% Tween 80 solution and delivered to zebrafish by immersion in home tank water in final concentrations of 25 and 150 µL/L. All doses were selected based on the previous studies of our group [40 (link),41 (link)]. The treatment was administered once for 17 consecutive days (7 days pre-treatment and 10 days during behavioral assessment,Figure 7 ). The zebrafish model of AD was induced by adding the fish to 100 µM SCOP solution for 30 min before starting each behavioral test. After SCOP administration, groups III and IV were treated acutely, for 3 min before testing, with GAL 1 mg/L and IMP 20 mg/L, respectively, and were considered the positive controls of our study (Figure 7 ).
The animals were assigned to 6 experimental groups (10 fish/group) as follows: (I) Control; (II) SCOP (fish treated with 100 µM SCOP); (III) SCOP + GAL 1 mg/L (fish treated with 100 µM SCOP and 1 mg/L GAL); (IV) SCOP + IMP 20 mg/L (fish treated with 100 µM SCOP and 20 mg/L IMP); (V) SCOP + GCEO 25 µL/L (fish treated with 100 µM SCOP and 25 µL/L GCEO); (VI) SCOP + GCEO 150 µ/L (fish treated with 100 µM SCOP and 150 µL/L GCEO). Groups I, II, III and IV received 1% Tween 80 as vehicle. GCEO was prepared in 1% Tween 80 solution and delivered to zebrafish by immersion in home tank water in final concentrations of 25 and 150 µL/L. All doses were selected based on the previous studies of our group [40 (link),41 (link)]. The treatment was administered once for 17 consecutive days (7 days pre-treatment and 10 days during behavioral assessment,
Adult
Animals
Behavior Test
Electric Conductivity
Ethics Committees
Europeans
Faculty
Females
Fishes
GAL-1
Males
Product R
Strains
Submersion
Tween 80
Zebrafish
Statistical analyses were conducted using SPSS software (version 22.0; IBM, Armonk, NY, USA), with p < 0.05 indicating statistical significance. Questionnaire data were examined using descriptive statistics and logistic regression. Logistic regression analysis was applied to determine the potential risk factors associated with the discomfort symptoms in each body site of the participants. The factors surveyed by the questionnaire covered personal information, job characteristics (individual factors, daily primary tasks, task requirements), previous injuries, and the usage of personal assistive devices. The odds ratio (OR) was employed to compare the relative odds of the occurrence of certain variables. The Pearson product–moment correlation coefficient r was used to explore the test–retest reliability of the NMQ responses for the preselected Taiwanese and Thai workers. In addition, the chi-square test was carried out to determine the significance of the difference in the prevalence of the discomfort of various body sites between the two worker groups.
Human Body
Injuries
Product R
Self-Help Devices
Thai
Workers
Top products related to «Product R»
Sourced in United States
Picrotoxin is a naturally occurring compound that functions as a non-competitive antagonist of gamma-aminobutyric acid (GABA) receptors. It is commonly used in scientific research as a tool to investigate GABA receptor function and modulation.
Sourced in United States
Thapsigargin is a natural product compound obtained from the plant Thapsia garganica. It functions as a specific and potent inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump, which plays a crucial role in regulating intracellular calcium homeostasis.
Sourced in United States, Germany
Heparin is a naturally occurring anticoagulant that is widely used in various laboratory and medical applications. It is a highly sulfated glycosaminoglycan that plays a crucial role in the regulation of blood coagulation. Heparin functions by enhancing the activity of antithrombin, a protein that inhibits the action of certain enzymes involved in the blood clotting process.
Sourced in United Kingdom
Kynurenic acid is a chemical compound found naturally in the human body. It is a product of the kynurenine pathway, which is involved in the metabolism of the amino acid tryptophan. Kynurenic acid has various biochemical properties and functions, but a detailed description of its intended use is not available.
Sourced in United States
U73122 is a phosphoinositide-specific phospholipase C (PI-PLC) inhibitor. It functions by inhibiting the activity of PI-PLC, which is involved in signal transduction pathways.
GDP-β-S is a non-hydrolyzable analog of guanosine diphosphate (GDP). It is commonly used as a tool in biochemical research to study the role of GDP and guanine nucleotide-binding proteins in various cellular processes.
Chelerythrine is a small molecule inhibitor that acts as a potent and selective inhibitor of protein kinase C (PKC). It is commonly used as a research tool to study the role of PKC in various cellular processes.
Sourced in United Kingdom
The ML 133 is a laboratory equipment product designed for conducting various scientific experiments and analyses. It is a versatile tool that can be utilized across different research and development fields. The core function of the ML 133 is to provide a controlled environment for sample preparation, testing, and data collection, but a detailed description of its capabilities and intended use is not available at this time.
U73343 is a selective inhibitor of phosphoinositide-specific phospholipase C. It acts by inhibiting the activity of phospholipase C, which plays a role in intracellular signal transduction pathways.
Bisindolylmaleimide II (Bis II) is a small molecule that functions as a protein kinase C (PKC) inhibitor. It is commonly used in research applications to study the role of PKC in cellular processes.
More about "Product R"
Discover the power of PubCompare.ai, an innovative AI-powered research platform that streamlines the discovery and comparison of scientific protocols.
Leveraging extensive data from literature, preprints, and patents, this cutting-edge technology empowers researchers to identify the most relevant and effective protocols for their needs.
PubCompare.ai's intuitive tools for protocol alignment and optimization help users optimize their research workflow and stay ahead of the curve.
Experience the future of research today with this seamless user experince.
Explore the world of scientific protocols with PubCompare.ai, where you can locate and compare protocols from a vast database of literature, preprints, and patents.
Utilize the platform's AI-driven analysis to identify the best protocols and products for your specific research needs.
From Picrotoxin and Thapsigargin to Heparin, Kynurenic acid, and beyond, PubCompare.ai provides a comprehensive solution for researchers.
Streamline your workflow with the platform's intuitive tools, including protocol alignment and optimization features, and experience the future of research with this cutting-edge technology.
Stay ahead of the curve and optimize your research process with PubCompare.ai's seamless user experince.
Discover the power of this AI-powered platform and unleash your full potential as a researcher today.
Leveraging extensive data from literature, preprints, and patents, this cutting-edge technology empowers researchers to identify the most relevant and effective protocols for their needs.
PubCompare.ai's intuitive tools for protocol alignment and optimization help users optimize their research workflow and stay ahead of the curve.
Experience the future of research today with this seamless user experince.
Explore the world of scientific protocols with PubCompare.ai, where you can locate and compare protocols from a vast database of literature, preprints, and patents.
Utilize the platform's AI-driven analysis to identify the best protocols and products for your specific research needs.
From Picrotoxin and Thapsigargin to Heparin, Kynurenic acid, and beyond, PubCompare.ai provides a comprehensive solution for researchers.
Streamline your workflow with the platform's intuitive tools, including protocol alignment and optimization features, and experience the future of research with this cutting-edge technology.
Stay ahead of the curve and optimize your research process with PubCompare.ai's seamless user experince.
Discover the power of this AI-powered platform and unleash your full potential as a researcher today.